Analysis of ATP7A Expression and Ceruloplasmin Levels As Biomarkers in Patients Undergoing Neoadjuvant Chemotherapy for Advanced High-Grade Serous Ovarian Carcinoma

Overview

Journal Int J Mol Sci

Publisher MDPI

Specialties Biochemistry
Chemistry
Molecular Biology

Date 2024 Sep 28

PMID 39337685

Authors

David Lukanovic

Sara Polajzer

Miha Matjasic

Borut Kobal

Katarina cerne

Affiliations

Soon will be listed here.

Abstract

Ovarian cancer (OC), particularly high-grade serous carcinoma (HGSC), is a leading cause of gynecological cancer mortality due to late diagnosis and chemoresistance. While studies on OC cell lines have shown that overexpression of the ATP7A membrane transporter correlates with resistance to platinum-based drugs (PtBMs) and cross-resistance to copper (Cu), clinical evidence is lacking. The functionality of ceruloplasmin (CP), the main Cu-transporting protein in the blood, is dependent on, among other things, ATP7A activity. This study investigated ATP7A expression and CP levels as potential biomarkers for predicting responses to PtBMs. We included 28 HGSC patients who underwent neoadjuvant chemotherapy (NACT). ATP7A expression in ovarian and peritoneal tissues before NACT and in peritoneal and omental tissues after NACT was analyzed via qPCR, and CP levels in ascites and plasma were measured via ELISA before and after NACT. In total, 54% of patients exhibited ATP7A expression in pretreatment tissue (ovary and/or peritoneum), while 43% of patients exhibited ATP7A expression in tissue after treatment (peritoneum and/or omentum). A significant association was found between higher ATP7A expression in the peritoneum before NACT and an unfavorable CA-125 elimination rate constant k (KELIM) score. Patients with omental ATP7A expression had significantly higher plasma mean CP levels before NACT. Plasma CP levels decreased significantly after NACT, and higher CP levels after NACT were associated with a shorter platinum-free interval (PFI). These findings suggest that the ATP7A transporter and CP have the potential to serve as predictive markers of chemoresistance, but further research is needed to validate their clinical utility.

References

You B, Freyer G, Gonzalez-Martin A, Lheureux S, McNeish I, Penson R . The role of the tumor primary chemosensitivity relative to the success of the medical-surgical management in patients with advanced ovarian carcinomas. Cancer Treat Rev. 2021; 100:102294. DOI: 10.1016/j.ctrv.2021.102294. View

Mansoori B, Mohammadi A, Davudian S, Shirjang S, Baradaran B . The Different Mechanisms of Cancer Drug Resistance: A Brief Review. Adv Pharm Bull. 2017; 7(3):339-348. PMC: 5651054. DOI: 10.15171/apb.2017.041. View

Ferlay J, Soerjomataram I, Dikshit R, Eser S, Mathers C, Rebelo M . Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012. Int J Cancer. 2014; 136(5):E359-86. DOI: 10.1002/ijc.29210. View

Cornelison R, Llaneza D, Landen C . Emerging Therapeutics to Overcome Chemoresistance in Epithelial Ovarian Cancer: A Mini-Review. Int J Mol Sci. 2017; 18(10). PMC: 5666852. DOI: 10.3390/ijms18102171. View

Nayak S, Bhat V, Upadhyay D, Udupa S . Copper and ceruloplasmin status in serum of prostate and colon cancer patients. Indian J Physiol Pharmacol. 2003; 47(1):108-10. View

Kobal B, Noventa M, Cvjeticanin B, Barbic M, Meglic L, Herzog M . Primary debulking surgery versus primary neoadjuvant chemotherapy for high grade advanced stage ovarian cancer: comparison of survivals. Radiol Oncol. 2018; 52(3):307-319. PMC: 6137361. DOI: 10.2478/raon-2018-0030. View

Samimi G, Safaei R, Katano K, Holzer A, Rochdi M, Tomioka M . Increased expression of the copper efflux transporter ATP7A mediates resistance to cisplatin, carboplatin, and oxaliplatin in ovarian cancer cells. Clin Cancer Res. 2004; 10(14):4661-9. DOI: 10.1158/1078-0432.CCR-04-0137. View

Patil M, Lavanya T, Kumari C, Shetty S, Gufran K, Viswanath V . Serum ceruloplasmin as cancer marker in oral pre-cancers and cancers. J Carcinog. 2021; 20:15. PMC: 8531576. DOI: 10.4103/jcar.jcar_10_21. View

Lane D, Matte I, Garde-Granger P, Laplante C, Carignan A, Rancourt C . Inflammation-regulating factors in ascites as predictive biomarkers of drug resistance and progression-free survival in serous epithelial ovarian cancers. BMC Cancer. 2015; 15:492. PMC: 4486134. DOI: 10.1186/s12885-015-1511-7. View

10.

Nakayama K, Kanzaki A, Terada K, Mutoh M, Ogawa K, Sugiyama T . Prognostic value of the Cu-transporting ATPase in ovarian carcinoma patients receiving cisplatin-based chemotherapy. Clin Cancer Res. 2004; 10(8):2804-11. DOI: 10.1158/1078-0432.ccr-03-0454. View

11.

Turajlic S, Swanton C . Metastasis as an evolutionary process. Science. 2016; 352(6282):169-75. DOI: 10.1126/science.aaf2784. View

12.

Rose P . Ovarian cancer recurrence: is the definition of platinum sensitivity modified by PARPi, bevacizumab or other intervening treatments? : a clinical perspective. Cancer Drug Resist. 2022; 5(2):415-423. PMC: 9255234. DOI: 10.20517/cdr.2022.01. View

13.

Kalayda G, Wagner C, Buss I, Reedijk J, Jaehde U . Altered localisation of the copper efflux transporters ATP7A and ATP7B associated with cisplatin resistance in human ovarian carcinoma cells. BMC Cancer. 2008; 8:175. PMC: 2442842. DOI: 10.1186/1471-2407-8-175. View

14.

Colombo N, Sessa C, Bois A, Ledermann J, McCluggage W, McNeish I . ESMO-ESGO consensus conference recommendations on ovarian cancer: pathology and molecular biology, early and advanced stages, borderline tumours and recurrent disease†. Ann Oncol. 2019; 30(5):672-705. DOI: 10.1093/annonc/mdz062. View

15.

Chen J, Jiang Y, Shi H, Peng Y, Fan X, Li C . The molecular mechanisms of copper metabolism and its roles in human diseases. Pflugers Arch. 2020; 472(10):1415-1429. DOI: 10.1007/s00424-020-02412-2. View

16.

Skof E, Merlo S, Pilko G, Kobal B . The role of neoadjuvant chemotherapy in patients with advanced (stage IIIC) epithelial ovarian cancer. Radiol Oncol. 2016; 50(3):341-6. PMC: 5024662. DOI: 10.1515/raon-2016-0034. View

17.

Onizuka K, Migita S, Yamada H, Matsumoto I . [Serum protein fractions in patients with laryngeal cancer undergoing radiation therapy. Possibility as a prognostic factor]. Fukuoka Igaku Zasshi. 1999; 90(2):46-58. View

18.

Sant M, Chirlaque Lopez M, Agresti R, Sanchez Perez M, Holleczek B, Bielska-Lasota M . Survival of women with cancers of breast and genital organs in Europe 1999-2007: Results of the EUROCARE-5 study. Eur J Cancer. 2015; 51(15):2191-2205. DOI: 10.1016/j.ejca.2015.07.022. View

19.

Lai Y, Kuo C, Kuo M, Chen H . Modulating Chemosensitivity of Tumors to Platinum-Based Antitumor Drugs by Transcriptional Regulation of Copper Homeostasis. Int J Mol Sci. 2018; 19(5). PMC: 5983780. DOI: 10.3390/ijms19051486. View

20.

Elsnerova K, Mohelnikova-Duchonova B, Cerovska E, Ehrlichova M, Gut I, Rob L . Gene expression of membrane transporters: Importance for prognosis and progression of ovarian carcinoma. Oncol Rep. 2016; 35(4):2159-70. DOI: 10.3892/or.2016.4599. View